Future FinTech, a leading provider of comprehensive financial and digital technology services, announced that on January 7, 2026, its wholly-owned subsidiary, Future FinTech Hong Kong Limited, signed a framework agreement to acquire 100 percent of TransGen SC Tech Limited.
Health Technology Insights: GenSight Biologics Gets CUA for GS010/LUMEVOQ in France
The agreement outlines the preliminary terms for the acquisition, which is expected to be finalized within 90 days, pending due diligence and a financial review of TransGen. A formal purchase agreement will be signed once the evaluation is completed successfully, followed by a definitive acquisition contract. TransGen has developed a strong foundation in biofactor research and development, working with naturally occurring compounds that support normal physiological functions and contribute to disease prevention and overall wellness.
The company is focused on high-value therapeutic areas, particularly treatments for diabetes and Alzheimer’s disease. In addition, TransGen is advancing research on microalgal extracellular vesicles, naturally secreted nanoparticles from microalgae that serve as next-generation carriers for targeted drug delivery and diagnostics by transferring beneficial biological molecules.
Health Technology Insights: Pulse Biosciences Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
The company holds 26 patents and utility model rights, along with multiple certifications, including Level 2 Biosafety Laboratory Certification regulated by China’s National Health Commission and a Human Umbilical Cord Mesenchymal Stem Cells Qualification Certificate issued by the National Institutes for Food and Drug Control. TransGen has also contributed to developing the group standard for isolation and preparation of adipose-derived mesenchymal stem cells and the local standard for management of human mesenchymal stem cell banks, demonstrating its recognized leadership and technological strength in the biomedical sector.
Gai Wei, Director of TransGen, said that the company is committed to advancing technology and industrial applications in the biomedical field and that the partnership with Future FinTech provides a strong platform for expanding internationally. Hu Li, CEO of Future FinTech, stated that the acquisition aligns with the company’s strategy to enter the biomedical sector, noting that TransGen is well-positioned for growth in a market driven by aging populations and increasing healthcare spending.
Li highlighted that Future FinTech’s expertise in risk modeling, securitization, and capital markets can create innovative funding solutions for medical technologies and help turn biomedical research into investable projects. He added that secure identity, payments, and data sharing are essential in both finance and healthcare, and this acquisition will support TransGen’s industrial development while generating long-term value for shareholders.
Health Technology Insights: Bristol Myers Squibb Partners with U.S. to Boost Drug Access
To participate in our interviews, please write to our HealthTech Media Room at info@intentamplify.com
